8-K 1 a12-12229_28k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event Reported): May 15, 2012

 

 

THERAVANCE, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

(State or Other Jurisdiction of
Incorporation)

 

000-30319

(Commission File Number)

 

94-3265960

(I.R.S. Employer Identification Number)

 

901 Gateway Boulevard
South San Francisco, California 94080
(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 3.02              Unregistered Sales of Equity Securities.

 

On May 16, 2012, Theravance, Inc. (the “Company”) completed the sale of 10,000,000 shares of its common stock (the “Shares”) to Glaxo Group Limited, a limited liability company organized under the laws of England and Wales (the “Investor”), at a price of $21.2887 per Share (the “Private Placement”).  The Private Placement was made pursuant to the Common Stock Purchase Agreement (the “Common Stock Purchase Agreement”) previously described in and attached as Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on April 2, 2012.

 

The Private Placement resulted in aggregate gross proceeds of $212,887,000 before deducting transaction expenses. Neither the Company nor the Investor engaged any investment advisors with respect to the Private Placement, and no finders’ fees were paid or will be paid to any party in connection therewith. The Shares were issued and sold by the Company in reliance upon an exemption from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.

 

Item 5.07  Submission of Matters to a Vote of Security Holders.

 

(a)                                 The Annual Meeting of Stockholders of the Company was held on May 15, 2012.

 

(b)                                 The nominees listed below were elected directors with the respective votes set forth opposite their names:

 

 

 

Votes for

 

Votes withheld

 

Rick E Winningham

 

77,155,230

 

287,347

 

Henrietta Holsman Fore

 

77,219,207

 

223,370

 

Robert V. Gunderson, Jr.

 

76,361,775

 

1,080,802

 

Arnold J. Levine. Ph.D.

 

77,215,827

 

226,750

 

Burton G. Malkiel, Ph.D.

 

77,227,639

 

214,938

 

Peter S. Ringrose, Ph.D.

 

77,120,464

 

322,113

 

William H. Waltrip

 

77,192,436

 

250,141

 

George M. Whitesides, Ph.D.

 

76,890,476

 

552,101

 

William D. Young

 

76,891,476

 

551,101

 

 

2


 

The stockholders approved the Company’s 2012 Equity Incentive Plan.  The voting results are set forth below:

 

For

 

Against

 

Abstain

 

74,591,514

 

2,848,788

 

2,275

 

 

In a non-binding advisory vote, the stockholders voted to approve the compensation of the Company’s named executive officers disclosed in the Company’s 2012 proxy statement.  The voting results are set forth below:

 

For

 

Against

 

Abstain

 

60,048,732

 

17,337,355

 

56,490

 

 

The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2012.  The voting results are set forth below:

 

For

 

Against

 

Abstain

 

80,671,324

 

136,166

 

56,091

 

 

The stockholders approved the sale and issuance of 10,000,000 shares of the Company’s common stock in a private placement to Glaxo Group Limited.  The voting results are set forth below:

 

For

 

Against

 

Abstain

 

77,359,354

 

74,741

 

8,482

 

 

3


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

THERAVANCE, INC.

 

 

 

 

Dated: May 17, 2012

By:

/s/ Michael W. Aguiar

 

 

Michael W. Aguiar

 

 

Chief Financial Officer

 

4